Stelara(通用名：ustekinumab)顺应症： 中重度银屑病 ( Moderate to severe plaque psoriasis )出产商：J&J''s Centocor Ortho Biotech核准日子：9月25日强生公司旗下Centocor开发的新式单克隆抗体ustekinumab被核准用于中重...
基于20个网页-相关网页
用两种方法来评价银屑病甲的目标指甲在治疗前、中、后的严重度。
Two different methods were used to assess the severity of nail psoriasis in the target nail before, during, and after treatment.
普通人群发病率约为2%，其中30%为中到重度银屑病，但迄今为止，治疗手段仍然有限。
Around 2% of the population suffer from the disease, with about 30% of cases considered moderate to severe, but until now treatment options have been limited.
应用推荐